Status:
TERMINATED
Diagnostic Accuracy of SurePath™ in EUS-FNA
Lead Sponsor:
Seoul National University Hospital
Conditions:
Submucosal Tumor of Gastrointestinal Tract
Eligibility:
All Genders
19+ years
Brief Summary
It is a prospective randomized controlled study to evaluate the diagnostic accuracy of SurePath™ liquid-based cytology in endoscopic ultrasound-guided sampling.
Detailed Description
The SurePath™ has been approved by the FDA since 1997. Investigators want to compare the diagnostic accuracy of SurePath™ liquid based cytology and conventional smear cytology(CSC) in EUS-FNA sampling...
Eligibility Criteria
Inclusion
- Patients who signed the agreement after the explanation
- Patients suspected of esophageal, gastric, duodenal subepithelial tumors, periesophageal and perigastric lymph nodes from radiological(CT, MR, ultrasound) or endoscopic examinations.
Exclusion
- Those who did not agree with the study
- Patients younger than 19 years of age
- Serious mental patients
- Patients with severe accompanying diseases (ESRD, advanced COPD, severe heart failure, sever mental illness)
- Pregnant women
- If EUS is difficult due to previous surgery (Billroth II or TG with R-en-Y)
- Patient with blood clotting abnormality
- If there is a risk of tract seeding after examination
Key Trial Info
Start Date :
April 9 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 30 2023
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT05394129
Start Date
April 9 2019
End Date
January 30 2023
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea